As active contributors in research, sometimes it’s nice to take a step back and reflect how our work evolves from novel treatment to everyday practice. So much of how we choose to live our life now was determined by past evidence. But with the volume of information out there, it’s difficult to sift out the […]
Read More
In testament to George Clinical’s operational experience and ability, we recently completed a Chinese registration trial for a mid-sized global pharmaceutical with excellent results
Read More
George Clinical, a leading Asia-Pacific CRO, is wholly owned by The George Institute, a world leading medical research institute focused on chronic disease. Our model sees us forming integrated project teams with our scientific thought leaders. The Neurological & Mental Health unit, one of the many divisions within The George Institute, has led many clinical […]
Read MoreEffective management of diseases such as hypertension requires more than drug therapy, but also a change in diet and lifestyle.
Read MoreA randomised, double-blind trial examining the effects of an ACE inhibitor-based blood pressure lowering regimen on the risk of stroke among patients with a history of cerebrovascular disease.
Read MoreA randomised controlled double-blind study comparing the effects of saline versus albumin on mortality in 6,997 patients, with up to 30 days of follow-up. Saline vs Albumin Read more about the SAFE trial on The George Institute website This trial was completed under budget and ahead of schedule, with results published in The New England […]
Read MoreAction in Diabetes Read more about the ADVANCE trial on The George Institute website A factorial, randomised controlled trial study designed to determine the effects of intensive blood pressure lowering and glucose control on cardiovascular risks among type 2 diabetes patients. Covering both advanced economies in North America and Western Europe and emerging economies in […]
Read MoreAs active contributors in research, sometimes it’s nice to take a step back and reflect how our work evolves from novel treatment to everyday practice.
Read MoreEvidence is increasing of the benefits, without increased risks, of using dual antiplatelet therapy – aspirin and clopidogrel – as soon as possible and continued for up to 3-months in patients with minor acute ischaemic stroke or transient ischaemic stroke (TIA), so-called mini-strokes. The evidence is derived from multiple randomised controlled trials, including a recent […]
Read MoreThe recent SAVOR-TIMI 53 (saxagliptin) and EXAMINE (alogliptin) trials recently reported the effects of the DPPIV inhibitor class of glucose lowering agents in people with diabetes. As required by the US FDA, both drugs were found not to increase cardiovascular risk, allowing the agents to be registered for use in that country. Good news, it would […]
Read More
